Loading study record…
Loading study record…
The purpose of this trial is to investigate a novel treatment for cannabis dependence: cannabidiol. Between 96 and 168 young people who want to quit cannabis and meet criteria for moderate cannabis use disorder (DSM-5) will be recruited from the community. Stage one aims to identify the Most Effective Dose (MEDmg) of oral cannabidiol for reducing cannabis use over four treatment weeks. Stage two will determine whether the MED identified in stage 1 can offer an effective treatment for cannabis dependence.
Locally preserved from ClinicalTrials.govOpen ClinicalTrials.govlast source update 2018-10-24
What this record can show
This locally preserved record separates the registered protocol from source-reported registry results. Neither is a treatment recommendation.
Registry facts
Linked local records
Local links use governed condition terms or exact source-reported intervention names. They are navigation candidates, not efficacy claims.
Research network
Interventions
Eligibility
primary outcomes
Time frame: up to 4 weeks
This study has two stages. This is the primary endpoint criteria for stage 1.
Time frame: up to 4 weeks
This study has two stages. This is the primary endpoint criteria for stage 1.
Time frame: up to 4 weeks
This study has two stages. This is the primary endpoint criteria for stage 2.
Time frame: week 4
This study has two stages. This is the primary endpoint criteria for stage 2.
secondary outcomes
Time frame: Up to 28 weeks
Psychological Wellbeing, Cognition and Endocannabinoids will be measured by questionnaire methods, neuropsychological testing and biological samples.
Publications